Protagonist Therapeutics, Inc — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d9fc8233-ba4f-484e-b286-69ce4f9aada3/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $46.0M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-019696 |
| FY 2024 | $434.4M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001317 |
| FY 2023 | $60.0M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001850 |
| FY 2022 | $26.6M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003906 |
| FY 2021 | $27.4M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002385 |
| FY 2020 | $28.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-22-002385 |
| FY 2019 | $231.0k | 2019-01-01 – 2019-12-31 | evidence 0001558370-22-002385 |
| FY 2018 | $30.9M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001853 |
| FY 2017 | $20.1M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-001853 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Protagonist Therapeutics, Inc — all facts · Net Income · Operating Income